| Literature DB >> 27612668 |
James A McCubrey1, Dariusz Rakus2, Agnieszka Gizak2, Linda S Steelman3, Steve L Abrams3, Kvin Lertpiriyapong4, Timothy L Fitzgerald5, Li V Yang6, Giuseppe Montalto7, Melchiorre Cervello8, Massimo Libra9, Ferdinando Nicoletti9, Aurora Scalisi10, Francesco Torino11, Concettina Fenga12, Luca M Neri13, Sandra Marmiroli14, Lucio Cocco15, Alberto M Martelli15.
Abstract
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that participates in an array of critical cellular processes. GSK-3 was first characterized as an enzyme that phosphorylated and inactivated glycogen synthase. However, subsequent studies have revealed that this moon-lighting protein is involved in numerous signaling pathways that regulate not only metabolism but also have roles in: apoptosis, cell cycle progression, cell renewal, differentiation, embryogenesis, migration, regulation of gene transcription, stem cell biology and survival. In this review, we will discuss the roles that GSK-3 plays in various diseases as well as how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTOR, Ras/Raf/MEK/ERK, Wnt/beta-catenin, hedgehog, Notch and TP53. Mutations that occur in these and other pathways can alter the effects that natural GSK-3 activity has on regulating these signaling circuits that can lead to cancer as well as other diseases. The novel roles that microRNAs play in regulation of the effects of GSK-3 will also be evaluated. Targeting GSK-3 and these other pathways may improve therapy and overcome therapeutic resistance.Entities:
Keywords: Akt; GSK-3; Hedgehog; Notch; PI3K; Targeted therapy; Therapy resistance; Wnt/beta-catenin; mTOR
Mesh:
Substances:
Year: 2016 PMID: 27612668 DOI: 10.1016/j.bbamcr.2016.09.004
Source DB: PubMed Journal: Biochim Biophys Acta ISSN: 0006-3002